NCT05501886Phase 3Active not recruiting

Gedatolisib Plus Fulvestrant With or Without Palbociclib vs Standard-of-Care for the Treatment of Patients With Advanced or Metastatic HR+/HER2- Breast Cancer (VIKTORIA-1)

Study sponsor: Celcuity Inc · CELC

Primary completion is the date data collection ends for the main study measures, not when results are published.

Primary completion2026-06-30Estimated
Enrollment · participants701Estimated
Source updated2026-02-10Last update listed in the registry record

Changes to this trial

Last 12 months
Filters
Clear filters

· 2 fields changed

Primary completion date changed

Before: 30 Jun 2025. After: 30 Jun 2026.

Recruitment status changed

Before: Recruiting. After: Active not recruiting.

Check registry source

Explore older trial changes

Upgrade to Pro to see the full available history for this trial.

Upgrade to Pro Illustrative preview